1. Home
  2. XNET vs DCTH Comparison

XNET vs DCTH Comparison

Compare XNET & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$5.66

Market Cap

356.5M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.28

Market Cap

323.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNET
DCTH
Founded
2003
1988
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
356.5M
323.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
XNET
DCTH
Price
$5.66
$9.28
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
281.1K
504.2K
Earning Date
03-12-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
8740.73
N/A
EPS
20.16
0.03
Revenue
$401,918,000.00
$79,603,000.00
Revenue This Year
N/A
$132.21
Revenue Next Year
N/A
$33.88
P/E Ratio
$0.29
$269.81
Revenue Growth
27.19
251.54
52 Week Low
$2.64
$8.12
52 Week High
$11.03
$18.23

Technical Indicators

Market Signals
Indicator
XNET
DCTH
Relative Strength Index (RSI) 32.72 42.60
Support Level $5.55 $8.94
Resistance Level $6.12 $10.30
Average True Range (ATR) 0.32 0.49
MACD -0.03 -0.07
Stochastic Oscillator 22.19 30.36

Price Performance

Historical Comparison
XNET
DCTH

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: